Eventus Diagnostics in Miami raised a $2.72 million investment infusion that it will use to advance its Octava breast cancer diagnostic blood tests. They are designed for use along with annual mammograms to spot cancer or determine its absence by measuring ratios of autoantibodies produced in response to tumor-specific antigens. Octava tests have a CE mark and also recently won Israeli regulatory approval. More clinical studies are underway to provide additional data for a U.S. FDA submission. The funding comes from a new family office private investor, plus existing investors. Release